

22nd June 2005



**GlaxoSmithKline
Pharmaceuticals**

Stonemasons Way
Rathfarnham
Dublin 16
Ireland

Tel. +353-1-495 5000

Fax. +353-1-495 5105

www.gsk.com

Lamotrigine and risk of oral clefts

Dear

Following discussions with the Irish Medicines Board, GlaxoSmithKline (GSK) would like to inform you about important new safety information regarding Lamictal®.

- An increased risk of oral clefts associated with the use of Lamictal® during early pregnancy has recently been detected in one pregnancy registry.
- The product information for Lamictal® will be updated with this new information.
- The possible risk of oral clefts should be balanced against the needs for treatment. Sudden discontinuation of antiepileptic therapy may lead to breakthrough seizures with serious consequences for both the mother and the foetus and should be avoided.

Emerging data from the North American Antiepileptic Drug (NAAED) Pregnancy Registry suggest an association between Lamictal (lamotrigine) and an increased risk of non-syndromic oral clefts. Specifically, the NAAED Pregnancy Registry detected an elevated incidence of isolated, non syndromic cleft palate deformity occurring in infants exposed to lamotrigine monotherapy during the first trimester of pregnancy compared to the reference population used in this Registry.¹ Recently published data from the Registry report three cases of isolated, non syndromic cleft palate and two cases of isolated, non syndromic cleft lip without cleft palate in infants from 564 first trimester lamotrigine monotherapy exposures giving a rate of 8.9 per 1000.² This compares with a prevalence rate of 0.37 per 1000 seen in the general population of the Brigham and Women's Hospital (BWH) Surveillance Program (relative risk in lamotrigine-treated patients vs. BWH general population of 24; 95% CI 10.0-57.4). For reference, the overall rate of major malformations reported by the NAAED registry was 15/564 (2.7%, 27 per 1000) and not different from the reference population.

GlaxoSmithKline (Ireland) Ltd.

Registered in Ireland No. 15513
Registered office: Stonemasons Way, Rathfarnham,
Dublin 16, Ireland

Directors: A.J. Lynch
T.A. Tordoff (GB)
D.S. Redfern (GB)

The prevalence of oral clefts noted in the NAAED registry is also higher than the background prevalence of non-syndromic oral clefts reported in the literature, including studies from the United States, Australia and Europe. While different studies have differing results due to geographic and case ascertainment variations, the reported range is 0.50 to 2.16/1000³⁻¹⁷.


Whereas this finding has not been confirmed by other studies, GlaxoSmithKline (GSK) is in discussion with regulatory authorities around the world about these newly reported data and other relevant information, including outcomes in over 2000 pregnancies from other pregnancy registries, to further understand the significance of this finding. GSK is working with the Irish Medicines Board to update the prescribing and patient information to reflect these new data.

At this time, patients should be advised to notify their physicians if they become pregnant or intend to become pregnant during therapy. The possible risk of oral clefts associated with the use of lamotrigine during early pregnancy should be balanced against the needs for treatment. Sudden discontinuation of antiepileptic therapy may lead to breakthrough seizures with serious consequences for both the mother and the foetus and should be avoided. It should be noted that other antiepileptic drugs have also been associated with congenital malformations.

Any suspected adverse drug reactions should be notified to GSK and/or the Irish Medicines Board in the usual way.

Should you have any questions or require additional information, please contact GlaxoSmithKline on 1 800 244 255.

Yours sincerely,



Martina Dempsey PhD
Director of Medical and Regulatory Affairs
GlaxoSmithKline (Ireland) Limited

References:

1. Nelson K., Holmes L.B. Active Malformations Surveillance Program at Brigham and Women's Hospital in Boston. *New England J Medicine* 320:19-23, 1989.
2. Holmes LB, Wyszynski, DF, Baldwin EJ et al. Increased risk for non-syndromic cleft palate among infants exposed to lamotrigine during pregnancy (abstract). *Birth Defects Research Part A: Clinical and Molecular Teratology* 2006;76(5):318..
3. Tolarova MM, Cervenka J. Classification and birth prevalence of orofacial clefts. *Am J Med Genetics*. 1998; 75: 126-37.
4. Das S, Runnels R Jr, Smith J et al. Epidemiology of cleft lip and cleft palate in Mississippi. *South Med J*. 1995; 88: 437-42
5. Croen LA, Shaw GM, Wasserman CR et al. Racial and ethnic variations in the prevalence of orofacial clefts in California, 1983-92. *Am J Med Genetics*. 1998; 79: 42-47.
6. Hashmi SS, Waller DK, Langlois P, et al. Prevalence of non-syndromic oral clefts in Texas: 1995-1999. *Am J Med Genetics*. 2005; 134(A): 368-72.
7. DeRoo LA, Gaudino JA, Edmonds LD. Orofacial cleft malformations. Associations with maternal and infant characteristics in Washington state. *Birth Defects Research (A)*. 2003; 67: 637-42.
8. Menegotto BG, Salzano FM. Epidemiology of oral clefts in a large South American sample. *Cleft Palate Craniofacial Journal*. 1991; 28: 373-77.
9. Vallino-Napoli LD, Riley MM, Halliday J. An epidemiologic study of isolated cleft lip, palate or both in Victoria, Australia from 1983-2000. *Cleft Palate Craniofacial Journal*. 2004; 41: 185-94.
10. Christensen K. The 20th century Danish facial cleft population – epidemiological and genetic-epidemiological studies. *Cleft Palate Craniofacial Journal*. 1999; 36: 96-104.
11. Bille C, Skytthe A, Vach W et al. Parent's age and the risk of oral clefts. *Epidemiology*. 2005; 16: 311-16.
12. Kallen B. Maternal drug use and infant cleft lip/palate with special reference to corticoids. *Cleft Palate Craniofacial Journal*. 2003; 40(6): 624-8.
13. Becker M, Svensson H, Kallen B. Birth weight, body length, and cranial circumference in newborns with cleft lip or palate. *Cleft Palate Craniofacial Journal*. 1998; 35: 255-61.
14. Robert E, Kallen B, Harris J. The epidemiology of orofacial clefts. 1. Some general epidemiological characteristics. *J Craniofacial Genetics Developmental Biology*. 1996; 16: 234-41.
15. Stoll C, Alembik Y, Dott B et al. Associated malformations in cases with oral clefts. *Cleft Palate Craniofacial Journal*. 2000; 37: 41-47.

16. Teconi R, Clementi M, Turolla L. Theoretical recurrence risks for cleft lip derived from a population of consecutive newborns. *J Med Genetics*. 1988; 25: 243-46.

17. Harville EW, Wilcox AJ, Lie RT et al. Cleft lip and palate versus lip only: are they distinct defects? *Am J Epidemiol*. 2005; 162: 448-53.

